Acceleron Pharma Inc. (XLRN) Has Broken Out To A New High On Study Results
Markets2018-06-29
14 Views
Acceleron Pharma Inc. (XLRN) and Celgene (CELG) announced after the bell Thursday that the Phase 3 study of Luspatercept met its primary and key secondary endpoints.
Source: RTTNews
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
FSD Pharma (Nasdaq: HUGE) Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis
